论文部分内容阅读
目的:观察应用经鼻高流量氧疗对Ⅱ型急性呼吸衰竭患者的治疗效果。方法:将2017年7月至2019年12月徐州医科大学附属淮海医院收治的80例Ⅱ型急性呼吸衰竭患者作为研究对象，按随机数字表法将所有患者分为研究组(给予经鼻高流量氧疗)和对照组(给予无创正压通气治疗)，每组40例。统计治疗前及治疗2 h、12 h、24 h、48 h后的治疗效果、氧饱和度(SpOn 2)、PaOn 2、PaCOn 2、氧合指数、心率(HR)、平均动脉压(MAP)、呼吸频率(RR)及氧化应激指标；观察2组患者治疗后终点事件/合并症。n 结果:治疗2 h、12 h、24 h及48 h后，研究组治疗效果均明显优于对照组(n P值均<0.05)。治疗前，2组SpOn 2、PaOn 2、PaCOn 2及氧合指数相比差异无统计学意义；治疗2 h、12 h、24 h及48 h后，研究组SpOn 2、PaOn 2及氧合指数均高于对照组(n P值均<0.05)，而PaCOn 2低于对照组(n P值均<0.05)。治疗前，2组HR、MAP及RR相比差异无统计学意义；治疗2 h、12 h、24 h及48 h后，研究组HR、MAP及RR均低于对照组(n P值均<0.05)。治疗前，2组MDA及SOD相比差异无统计学意义；治疗2 h、12 h、24 h及48 h后，研究组MDA均低于对照组(n P值均<0.05)，SOD值均高于对照组(n P值均<0.05)。治疗后，研究组再插管率及腹泻发生率均低于对照组，但组间比较差异无统计学意义；谵妄发生率、拔管后ICU停留时间及ICU停留总时间均低于对照组(n P值均<0.05)。n 结论:经鼻高流量氧疗和无创正压通气治疗均可治疗Ⅱ型急性呼吸衰竭患者，但经鼻高流量氧疗治疗效果颇优，值得临床推广应用。“,”Objective:To observe the effects of transnasal high-flow oxygen therapy on the patients with type Ⅱ acute respiratory failure.Methods:80 patients with type Ⅱ acute respiratory failure admitted to the Affiliated Huaihai Hospital of Xuzhou Medical University from July 2017 to December 2019 were selected as the research subjects.According to the random number table method, all patients were divided into study group (given transnasal high-flow oxygen therapy) and control group (given non-invasive positive pressure ventilation therapy), 40 cases in each group.The treatment effect, oxygen saturation (SpOn 2), arterial partial pressure of oxygen (PaOn 2), arterial partial pressure of carbon dioxide (PaCOn 2), oxygenation index, heart rate (HR), mean arterial pressure (MAP), respiratory frequency (RR) and oxidative stress indicators before treatment and after treatment for 2, 12, 24, 48 hours were analyzed.The end-point events/comorbidities after treatment in the two groups were observed.n Results:After treatment for 2, 12, 24, 48 hours, the effect of the study group was significantly better than that of the control group (all n P<0.05). Before treatment, there was no significant difference in SpOn 2, PaOn 2, PaCOn 2 and oxygenation index between the two groups.After treatment for 2, 12, 24, 48 hours, SpOn 2, PaOn 2 and oxygenation index of the study group were all higher than those of the control group (all n P<0.05), and PaCOn 2 of the study group was lower than that of the control group (all n P<0.05). Before treatment, there was no significant difference in HR, MAP and RR between the two groups.After treatment for 2, 12, 24, 48 hours, HR, MAP and RR of the study group were lower than those of the control group (alln P<0.05). Before treatment, there was no significant difference in malondialdehyde (MDA) and superoxide dismutase (SOD) between the two groups.After treatment for 2, 12, 24, 48 hours, MDA of the study group was lower than that of the control group (alln P<0.05), and SOD of the study group was higher than that of the control group (alln P<0.05). After treatment, the reintubation rate and the incidence of diarrhea in the study group were lower than those in the control group, but there was no significant difference between the two groups.The incidence of delirium, stay time after extubation in intensive care unit, and total stay time in intensive care unit in the study group were lower than those in the control group (alln P<0.05).n Conclusions:Both transnasal high-flow oxygen therapy and non-invasive positive pressure ventilation can treat patients with type Ⅱ acute respiratory failure, but the effect of transnasal high-flow oxygen therapy is quite good, which is worthy of clinical application.